Point32Health and Takeda Pharmaceuticals America, Inc. signed a risk-sharing agreement around Takeda’s Alunbrig (brigatinib), a potent and selective tyrosine kinase inhibitor that is approved for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe